secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001437749-23-028296
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Phase 3 ARTEMIS-IGAN trial fails primary endpoint; narsoplimab BLA in IgAN discontinued
--------------------------------------------------------------------------------

- Narsoplimab did not achieve statistically significant reduction in proteinuria at 36 weeks vs placebo (24-hour UPE >2 g/day).
- Placebo group showed markedly greater proteinuria reduction than in other IgA nephropathy trials.
- Company will not submit BLA for narsoplimab in IgAN and is discontinuing the ARTEMIS-IGAN trial.
- Funds redirected to OMS906 (alternative pathway inhibitor) Phase 2/3 programs and narsoplimab BLA resubmission for HSCT-TMA.
- Narsoplimab was generally well tolerated with no new safety concerns.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774923028296/0001437749-23-028296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774923028296/omer20231012c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-028296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer